Holen Sie sich die Stockscreener-App
78.56
3.73%
2.80
Schlusskurs vom Vortag:
$75.76
Offen:
$74.83
24-Stunden-Volumen:
267.19K
Relative Volume:
0.17
Marktkapitalisierung:
$6.31B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-13.23
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-8.89%
1M Leistung:
+16.04%
6M Leistung:
+53.70%
1J Leistung:
+57.61%
1-Tages-Spanne:
$74.83
$78.80
1-Wochen-Bereich:
$73.03
$86.76
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
78.58 | 6.08B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.43 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.11 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.50 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
921.86 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.83 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
Panagora Asset Management Inc. Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
Will PTC Therapeutics Inc. (BH3) stock outperform global peersJuly 2025 Breakouts & Technical Buy Zone Confirmations - Newser
Can PTC Therapeutics Inc. (BH3) stock sustain breakout momentum - Newser
Why PTC Therapeutics Inc. stock could rally in 2025Weekly Trend Summary & Low Risk Entry Point Guides - Newser
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? - Yahoo Finance
PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says - MarketScreener
Prudential Financial Inc. Has $4.12 Million Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics stock price target raised to $55 from $50 at Goldman Sachs - Investing.com UK
Legal & General Group Plc Grows Stock Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? - AOL.com
Transcript : PTC Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 08 - MarketScreener
Can PTC Therapeutics Inc. (BH3) stock retain market dominance2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
How PTC Therapeutics Inc. (BH3) stock moves on employment dataQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
Is PTC Therapeutics Inc. stock a buy for dividend growth2025 Trading Recap & Reliable Volume Spike Trade Alerts - Newser
Why PTC Therapeutics Inc stock could rally in 2025Weekly Earnings Recap & Fast Gain Swing Trade Alerts - BỘ NỘI VỤ
Will PTC Therapeutics Inc. (BH3) stock deliver stable dividendsPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why - AOL.com
Cadrenal Therapeutics appoints PTC Therapeutics CMO to board By Investing.com - Investing.com Australia
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
PTC Therapeutics downgraded at RBC as Sephience sales priced in - MSN
PTC Therapeutics Shares Drop After RBC Downgrade - MarketScreener
PTC Therapeutics downgraded at RBC as Sephience sales priced in (PTCT:NASDAQ) - Seeking Alpha
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - The Manila Times
PTC Therapeutics stock downgraded by RBC Capital as shares near fair value - Investing.com Canada
RBC Downgrades PTC Therapeutics to Sector Perform From Outperform, Lifts Price Target to $91 From $82 - MarketScreener
(PTCT) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Elo Mutual Pension Insurance Co Makes New $689,000 Investment in PTC Therapeutics, Inc. $PTCT - MarketBeat
How The Sephience Launch Is Reshaping The Story For PTC Therapeutics’s Valuation - Yahoo Finance
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 - The Globe and Mail
Advantage Alpha Capital Partners LP Invests $204,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Stock on November 28, 2025: S&P SmallCap 600 Debut, Insider Selling and a 90% YTD Rally - ts2.tech
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 600 Health Care - MarketScreener
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P Composite 1500 - MarketScreener
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 600 - MarketScreener
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to S&P 1000 - MarketScreener
PTC Therapeutics (NASDAQ:PTCT) Insider Sells $6,001,672.32 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 11,801 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 35,572 Shares of Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Held Back By Insufficient Growth Even After Shares Climb 29% - 富途牛牛
PTC Therapeutics exec Almstead sells $6m in shares By Investing.com - Investing.com South Africa
Why hedge funds are buying PTC Therapeutics Inc. stockMarket Movers & Verified Technical Trade Signals - moha.gov.vn
37,734 Shares in PTC Therapeutics, Inc. $PTCT Bought by Segall Bryant & Hamill LLC - MarketBeat
Insider Sell: Allan Jacobson Sells 26,000 Shares of PTC Therapeu - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Director Emma Reeve Sells 10,000 Shares - MarketBeat
PTC Therapeutics exec Almstead sells $6m in shares - Investing.com
PTC Therapeutics Executives Engage in Significant Stock Transactions - TradingView
Officer Almstead Sells 35,572 ($2.9M) Of PTC Therapeutics Inc [PTCT] - TradingView
Dir Jacobson Sells 26,000 ($2.1M) Of PTC Therapeutics Inc [PTCT] - TradingView
[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity - Stock Titan
Why PTC Therapeutics Inc. stock is favored by pension fundsInsider Selling & High Conviction Investment Ideas - BỘ NỘI VỤ
PTC Therapeutics (NASDAQ:PTCT) Shares Gap UpTime to Buy? - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.13%
1.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):